Trial Profile
A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Oct 2016
Price :
$35
*
At a glance
- Drugs Suratadenoturev (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Oncolys BioPharma
- 31 Aug 2016 Results published in an Oncolys BioPharma media release.
- 03 Jun 2008 Interim results presented at the Annual Meeting of the American Society of Clinical Oncology 2008.
- 04 Apr 2008 New trial record.